Legend Biotech Corporation (LEGN)

45,30 +0,88 (+1,98%) Börsenschluss: 04:00PM EDT

Legend Biotech Corporation

2101 Cottontail Lane
Somerset, NJ 08873
United States
732 317 5050
https://www.legendbiotech.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 1.800

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Ying Huang Ph.D.	CEO & Director	N/A	N/A	1973
Ms. Lori A. Macomber CPA	Chief Financial Officer	N/A	N/A	1971
Mr. Doug Wallace	Vice President of Global Operations	N/A	N/A	N/A
Dr. Guowei Fang Ph.D.	Chief Scientific Officer & Head of Business Development	N/A	N/A	N/A
Joanne Choi	Senior Manager of Investor Relations	N/A	N/A	N/A
Mr. James Pepin J.D.	General Counsel	N/A	N/A	N/A
Deborah Wong	Executive Director of Strategic Marketing & Corporate Communications	N/A	N/A	N/A
Ms. Elaine Qian	VP & Global Head of Human Resources	N/A	N/A	N/A
Dr. Yuhong Qiu Ph.D.	Senior Vice President of Global Regulatory Affairs	N/A	N/A	N/A
Mr. Steven J. Gavel	Senior Vice President of Commercial Development, US & Europe	N/A	N/A	N/A

Die Beträge haben den Stand und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Corporate Governance

Legend Biotech Corporations ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.